Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | ASPH | Q12797 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583997 | 0.86 | PTGER1 (0.33) | PTGER1EPRS1CFTRASPHEGLN1 | |
| SCHEMBL1583276 | 0.86 | EPRS1 (0.35) | PTGER1EPRS1RXFP1CFTRASPH | |
| SCHEMBL13229138 | 0.84 | EPRS1 (0.34) | PTGER1EPRS1RXFP1CFTR | |
| SCHEMBL3690213 | 0.84 | NOTUM (0.44) | CFTR | |
| SCHEMBL3688490 | 0.83 | LDHA (0.43) | PTGER1TAS2R14PIN1 | |
| SCHEMBL3687750 | 0.82 | PTGS1 (0.42) | PTGER1EPRS1RXFP1HTT | |
| SCHEMBL1583898 | 0.82 | POLQ (0.35) | PTGER1 | |
| SCHEMBL1583475 | 0.78 | ERN1 (0.40) | PTGER1EPRS1 | |
| SCHEMBL3688388 | 0.78 | PIN1 (0.41) | PIN1 | |
| SCHEMBL3685886 | 0.78 | MARK3 (0.35) | PTGER1EPRS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | PTGER1 1091/4885EPRS1 1261/4885RXFP1 4676/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | PTGER1 1091/4885EPRS1 1261/4885RXFP1 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.